Idiopathic Pulmonary Fibrosis (IPF)

What is Idiopathic Pulmonary Fibrosis?

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by thickening and scarring (fibrosis) of the interstitial tissue that supports the alveoli – the tiny air‑sacs where oxygen is exchanged for carbon dioxide. The term idiopathic means the cause is unknown; the disease is not linked to an obvious external factor such as infection or a specific occupational exposure.

In IPF, the scar tissue makes the lungs stiff, reducing their ability to expand during inhalation. Over time, this leads to a gradual decline in oxygen delivery to the bloodstream, causing shortness of breath, persistent coughing, and a host of systemic effects. The disease most often presents in people aged 60 – 75, but it can affect younger adults as well.

Because the underlying cause is unknown, IPF is diagnosed after other potential causes of interstitial lung disease (ILD) have been excluded. It is a serious condition: the median survival after diagnosis is 3‑5 years, similar to that of many cancers. Early recognition and treatment can slow progression and improve quality of life.

Common Causes

Although IPF is “idiopathic,” several conditions and exposures can lead to a similar pattern of lung fibrosis. When a clear cause is identified, the disease is usually classified under a different name (e.g., “silicosis” or “asbestosis”). Understanding these related conditions helps clinicians rule out secondary causes.

• Environmental/occupational inhalants – silica dust, asbestos fibers, coal dust, and metal dust.
• Chronic smoking – long‑term tobacco use increases the risk of fibrotic lung disease.
• Gastro‑esophageal reflux disease (GERD) – micro‑aspiration of stomach acid can injure the alveolar epithelium.
• Autoimmune diseases – rheumatoid arthritis, systemic sclerosis, and mixed connective‑tissue disease can cause interstitial fibrosis.
• Medication‑induced fibrosis – certain chemotherapy agents (e.g., bleomycin, cyclophosphamide), anti‑arrhythmic drugs (amiodarone), and some antibiotics (nitrofurantoin).
• Radiation therapy – especially when directed at the chest.
• Genetic predisposition – rare familial forms linked to mutations in the surfactant protein genes (SFTPC, SFTPA2) or telomerase-related genes.
• Viral infections – chronic viral illnesses such as Epstein‑Barr virus have been explored as possible contributors.
• Post‑COVID‑19 fibrosis – severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection can leave lasting fibrotic changes in a subset of survivors.
• Other idiopathic interstitial pneumonias – such as nonspecific interstitial pneumonia (NSIP) that can evolve into a UIP (usual interstitial pneumonia) pattern similar to IPF.

Associated Symptoms

Symptoms of IPF are often subtle at first and may be mistaken for aging or a mild respiratory infection. Over time they become more pronounced.

• Shortness of breath (dyspnea) – initially on exertion, later at rest.
• Dry, “velcro‑like” cough – persistent, non‑productive, worsens at night.
• Fatigue and decreased exercise tolerance – due to reduced oxygen delivery.
• Clubbing of the fingertips – rounded nail beds, a classic sign of chronic hypoxia.
• Chest discomfort – a vague tightness rather than sharp pain.
• Weight loss – secondary to increased work of breathing.
• Joint or muscle aches – can accompany systemic inflammation.
• Sleep disturbances – caused by nocturnal dyspnea or GERD‑related coughing.

When to See a Doctor

Because early IPF can mimic benign conditions, it’s important to act promptly if you notice any of the following:

• Persistent shortness of breath that worsens over weeks or months.
• A dry cough that does not improve with typical cough remedies.
• Increasing fatigue that interferes with daily activities.
• Unexplained weight loss or loss of appetite.
• New or worsening clubbing of the fingers.
• History of exposure to dust, smoke, or chemicals combined with respiratory symptoms.

If you have any of these signs, schedule a primary‑care or pulmonology appointment promptly. Early referral can lead to earlier diagnosis, which is linked to better outcomes.

Diagnosis

Diagnosing IPF is a step‑wise process that integrates clinical history, imaging, lung function testing, and sometimes tissue sampling.

1. Detailed Medical History & Physical Exam

• Assessment of symptom onset, progression, and potential exposures.
• Physical signs: fine crackles (Velcro‑like) on lung auscultation, clubbing, cyanosis.

2. Pulmonary Function Tests (PFTs)

Typical findings include a restrictive pattern (reduced total lung capacity) and a markedly reduced diffusing capacity for carbon monoxide (DLCO), reflecting impaired gas exchange.

3. High‑Resolution Computed Tomography (HRCT) Scan

The HRCT is the cornerstone of radiologic diagnosis. The classic “usual interstitial pneumonia” (UIP) pattern includes:

• Subpleural, basal predominant reticulation.
• Honey‑comb cystic changes.
• Minimal ground‑glass opacities.

If a definite UIP pattern is seen, a lung biopsy may not be needed.

4. Laboratory Tests

Blood work helps rule out autoimmune and other systemic causes: antinuclear antibodies (ANA), rheumatoid factor, anti‑CCP, and specific myositis panels.

5. Lung Biopsy (when needed)

When imaging is inconclusive, a surgical (video‑assisted thoracoscopic) or transbronchial cryobiopsy can provide tissue for histopathology. The presence of a UIP pattern on biopsy supports an IPF diagnosis.

6. Multidisciplinary Discussion

International guidelines recommend that a team of pulmonologists, radiologists, and pathologists review each case to ensure accurate classification (ATS/ERS/JRS/ALAT 2022 guidelines).

Treatment Options

While there is currently no cure for IPF, several therapies can slow disease progression, alleviate symptoms, and improve quality of life.

1. Pharmacologic Therapies

• Pirfenidone (Esbriet) – an oral antifibrotic that reduces collagen deposition. Clinical trials show a 30‑40% reduction in decline of forced vital capacity (FVC) over one year (EMPA‑IPF, 2011).
• Nintedanib (Ofev) – a tyrosine‑kinase inhibitor targeting pathways involved in fibrosis. The INPULSIS trials demonstrated a 50% reduction in annual FVC decline.
• Supplemental oxygen – prescribed when resting or exertional oxygen saturation falls below 88 %.
• Antacid therapy – proton‑pump inhibitors may reduce micro‑aspiration in patients with GERD, though evidence is mixed.
• Vaccinations – influenza and pneumococcal vaccines are strongly recommended to prevent respiratory infections.

2. Pulmonary Rehabilitation

Structured exercise programs improve dyspnea, endurance, and overall health status. A typical program includes aerobic training, strength conditioning, breathing techniques, and counseling.

3. Symptom Management

• Cough suppressants – low‑dose opioids (e.g., codeine) or thalidomide can be useful under specialist supervision.
• Anxiety and depression treatment – counseling, cognitive‑behavioral therapy, or medications as indicated.

4. Advanced Therapies

• Lung transplantation – the only intervention known to extend survival markedly. Candidates are evaluated based on age, comorbidities, and functional status.
• Clinical trial participation – emerging antifibrotic agents, stem‑cell therapy, and novel immunomodulators are under investigation (see ClinicalTrials.gov).

5. Lifestyle & Home Care

• Quit smoking and avoid second‑hand smoke.
• Maintain a healthy weight; obesity can worsen dyspnea.
• Use a humidifier or air purifier to keep indoor air clean.
• Stay hydrated and practice paced breathing techniques.

Prevention Tips

Because IPF’s exact cause is unknown, “prevention” focuses on reducing known risk factors and protecting lung health.

• Avoid inhalational hazards – wear appropriate respiratory protection when exposed to dust, chemicals, or fumes.
• Stop smoking – cessation dramatically lowers the risk of developing interstitial lung disease.
• Manage GERD – elevate the head of the bed, avoid late meals, and use antacids if recommended.
• Vaccinate annually – flu and COVID‑19 vaccines reduce the chance of severe respiratory infections that could trigger or aggravate fibrosis.
• Regular medical follow‑up – if you have an autoimmune disease, occupational exposure, or a family history of ILD, schedule periodic lung assessments.
• Stay active – moderate aerobic exercise helps maintain lung capacity and overall cardiovascular health.

Emergency Warning Signs

If you experience any of the following, seek emergency medical care (call 911 or go to the nearest emergency department) immediately:

• Sudden worsening of shortness of breath at rest or with minimal activity.
• Sharp chest pain that does not improve with rest.
• Bluish discoloration of lips, fingertips, or face (cyanosis).
• Rapid heart rate (tachycardia) accompanied by dizziness or fainting.
• Severe coughing with blood‑tinged sputum.
• Sudden, unexplained swelling in the legs or abdomen (possible right‑heart failure).

References:

1. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association. “Idiopathic Pulmonary Fibrosis: Diagnosis and Management Guidelines.” Am J Respir Crit Care Med. 2022;205(8):e18‑e45.
2. Mayo Clinic. “Idiopathic Pulmonary Fibrosis.” Updated 2024. https://www.mayoclinic.org
3. National Heart, Lung, and Blood Institute (NHLBI). “Pulmonary Fibrosis.” 2023. https://www.nhlbi.nih.gov
4. Richeldi L, et al. “Efficacy and Safety of Nintedanib in IPF.” The New England Journal of Medicine. 2014;371:1211‑1220.
5. King TE, et al. “Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.” NEJM. 2011;364:2209‑2218.
6. World Health Organization. “Global Surveillance of Chronic Respiratory Diseases.” 2023.
7. Cleveland Clinic. “Pulmonary Rehabilitation for Interstitial Lung Disease.” 2024.
8. ClinicalTrials.gov. Search term: “idiopathic pulmonary fibrosis”. Accessed May 2026.